ABEO rises after Roth Capital initiates Buy; Fayuvi FDA approval
ABEO closed up 4% Thursday and added 2% after-hours after Roth Capital initiated coverage at Buy with a $17 target; Ultragenyx’s Fayuvi gene therapy received late-session FDA approval.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Roth Capital initiates Abeona Therapeutics at Buy
Roth Capital initiated coverage on Abeona Therapeutics with a $17.00 price target, reported via Benzinga/TradingView News.